571 related articles for article (PubMed ID: 34758782)
1. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.
Jin Z; Wang J; Sun J; Zhu C; Zhang J; Zhang B
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1794. PubMed ID: 37199321
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
[TBL] [Abstract][Full Text] [Related]
7. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
Wang LL; Xie YX; Liu Y
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):659-667. PubMed ID: 38305608
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.
Kato K; Doki Y; Chau I; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Makino T; Blum Murphy M; Amaya-Chanaga C; Patel A; Hu N; Matsumura Y; Kitagawa Y; Ajani J
Cancer Med; 2024 May; 13(9):e7235. PubMed ID: 38716626
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Jin Z; Zhao M
J Immunother; 2023 Sep; 46(7):262-270. PubMed ID: 37338278
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
Li D; Tang L; Hu J; Cao X; He Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Lee J; Kim B; Jung HA; La Choi Y; Sun JM
Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
[TBL] [Abstract][Full Text] [Related]
15. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
[TBL] [Abstract][Full Text] [Related]
17. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract][Full Text] [Related]
18. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
20. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
